Effect of Boswellia Serrata on Cognitive impairment in Multiple Sclerosis

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT2015042021862N1

Enrollment

Registered

2015-05-19

Start date

2014-07-23

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Multiple sclerosis. Multiple sclerosis

Interventions

Intervention 1: Boswellia Serrata, 600 mg, twice a day, for 2 months. Intervention 2: Placebo, twice a day, for 2 months.

Treatment - Drugs

Boswellia Serrata, 600 mg, twice a day, for 2 months

Placebo, twice a day, for 2 months

Eligibility

Sex/Gender

All

Age

15 Years to 56 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: Patients with Relapsing-Remitting MS (RRMS); Patients with cognitive impairment; Relapse free in the last 6 weeks before starting of assessments Exclusion criteria: Current major depression; Preexisting medical or psychiatric disorders associated with cognitive dysfunction; Developmental disease; Drug or alcohol abuse, Patients with Expanded Disability Status Scale (EDSS)>3; New MS attacks and received corticosteroids up to 6 weeks before the study and pregnant or breastfeeding

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Cognitive impairement. Timepoint: Before treatment, 2 months after treatment. Method of measurement: Questionnaire.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSiedeh Khatoun Mousavinejad

Ahvaz Judishapur University of Medical Sciences

mousavinejad.skh@ajums.ac.irmojtabanajafi2000@yahoo.com+98 613374001

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026